Cancer continues to be a major public health challenge due to therapeutic resistance, rising incidence, and financial burden. Although anti-programmed cell death-ligand 1 (PD-L1) immunotherapy has revolutionized cancer treatment, its efficacy as monotherapy re... ...

请注册登录后继续浏览